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INTRODUCTION
Mycoplasma pneumoniae is a well known causative agent of
acute respiratory infection in childhood. It is a cause of pri-
mary atypical pneumonia, but many infections are asymp-
tomatic or cause only mild symptoms, such as pharyngitis
and bronchitis (1). Thus clinical findings are seldom diag-
nostic for M. pneumoniae infection.
M. pneumoniae infections are endemic in large urban areas
and epidemic increases are observed at 3- to 7-yr intervals
(2-6). In Denmark the disease occurred in a regular pattern
of epidemics every 4.5 yr during the period 1958-1974 (2).
Epidemics with an interval of 7 yr were reported in Seattle,
U.S.A. in 1966-1967 and 1974 (3), and in Japan epidemic
peaks occurred regularly at 4-yr intervals during the period
1980-1992 (4). A few studies on epidemics of M. pneumoniae
infections have been undertaken in Korea (7-10), which des-
cribe epidemics occurring at 3- to 4-yr intervals. However,
these studies focused on the number of community acquired
pneumonia cases caused by M. pneumoniae among hospital-
ized patients, and no epidemiologic study of M. pneumoniae
infections has been conducted on the basis of a serologic diag-
nosis in subjects representing general population.
The standard laboratory methods for the diagnosis of M.
pneumoniae infections have been culture and serology. The
agent is fastidious and grows slowly, limiting the usefulness
of culture for routine purposes (11). Serology is more sensi-
tive for detecting acute infection than culture. A 4-fold rise
in antibody titer in acute and convalescent sera is considered
necessary for the diagnosis of current M. pneumoniae infection
(12). However, a significant rise in antibody titer can not be
demonstrated unless the first blood specimen is taken with-
in 10 days of the onset of illness (3) or unless convalescent
serum is obtained at proper time intervals (13). Furthermore,
serologic tests with paired sera are not suited for the detection
of asymptomatic infection. Thus most seroepidemiologic
studies confirmed the existence of epidemics by display of
the distribution of seropositive cases in time on the basis of
testing single serum samples (2, 14-16).
The aim of the present study was to describe the presence
of M. pneumoniae epidemics in a hospital-based population
by retrospective analysis of serologic data over a period of 4
yr. Special attention was paid to the relationship between
antibody titer to M. pneumoniae and sex, age, and atopy dur-
ing childhood.
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Distributions of Antibody Titers to Mycoplasma pneumoniae in 
Korean Children in 2000-2003
The aim of study was to describe Mycoplasma pneumoniae epidemics in a hospital-
based population. Special attention was paid to the relationship between antibody
titer to M. pneumoniae and sex, age, and atopy. During the eight 6-month periods
between January 2000 and December 2003, serum samples were obtained from
1,319 Korean children who presented with respiratory symptoms, and were exam-
ined for antibodies to M. pneumoniae using the indirect particle agglutination test.
Geometric mean antibody titers peaked in the second half of 2000 and then decreased
gradually, a second peak occurred in the second half of 2003. Likewise, the frequency
of high antibody titers (≥1:640) also peaked during these two periods. Antibody
titers in children aged 0-3 yr were lower than in older children during both peak peri-
ods and for 2 yr after the first peak. Sex and atopy had no effect on antibody titers.
During the years 2000-2003, geometric mean antibody titers and the frequencies
of high antibody titers varied with time. These changes suggest a cyclic pattern of
M. pneumoniae infection, with two epidemic peaks separated by 3 yr.
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MATERIALS AND METHODS
Subjects and study design
The study population comprised 1,319 Korea children
aged ≤15 yr, who presented at the outpatient clinic of Seoul
National University Hospital for the first time, with acute
or chronic respiratory symptoms. Respiratory symptoms
included cough, wheezing or other noisy breathing, a runny
or stuffed nose, or respiratory difficulties. Children with im-
munodeficiency disorder were excluded from the study. Dur-
ing the eight 6-month periods between January 2000 and
December 2003, serum samples were investigated for anti-
M. pneumoniae antibodies. The numbers of samples collected
in each period were; 123 and 111 in the first and second halves
of 2000, 147 and 167 in the first and second halves of 2001,
172 and 212 in the first and second halves of 2002, 203 and
184 in the first and second halves of 2003, respectively. Only
one sample was obtained per subject, and subjects enrolled
in one period were not included in any other period. The
mean±SD age of all subjects was 6.0±3.4 yr with a male to
female ratio of 2:1. Subjects were grouped according to age:
0-3 (n=417), 4-6 (n=508), and 7-15 yr (n=394), to allow
antibody titers to be examined by age. Parents provided writ-
ten informed consent for their children to participate in the
study. The study protocol was approved by the Hospital Ethics
Committee.
Serology
Anti-M. pneumoniae antibodies in serum specimens were
titrated using the indirect particle agglutination test (Sero-
dia-MycoII, Fujirebio, Japan), according to the manufacturer’s
instructions. This test is based on the principle that gelatin
particles sensitized with M. pneumoniae cell membrane com-
ponents are agglutinated in the presence of M. pneumoniae
antibody. Blood samples were drawn into Vacutainer SST
tubes (Becton Dickinson, Franklin Lakes, NJ, U.S.A.) and cen-
trifuged at 2,000 r.p.m. for 10 min. The separated serum was
stored at -20℃ until required for titer determination. The
cut-off value for a positive result was 1:40 (17). The demon-
stration of high antibody titers (≥1:640) was considered evi-
dence of recent M. pneumoniae infection (10, 18).
Atopy
In children aged 4 yr and over, atopy was defined as at least
one positive skin-prick test response (≥3 mm wheal diam-
eter) for a panel of 12 common aeroallergens, in the presence
of positive and negative controls (19). In children less than
4 yr old who could not undertake the skin-prick test, atopy
was defined as the presence of serum IgE antibodies ≥0.7
kU/L against at least one allergen and/or total IgE ≥200
kU/L (20, 21). Serum total and specific IgE were measured
using the Coat-A-Count
� Total IgE IRMA (Diagnostic Prod-
ucts Co., Los Angeles, CA, U.S.A.) and using the BLAST
system (Bio-Line, Brussels, Belgium), respectively. Whole
blood was collected by sterile venipuncture, serum was sep-
arated, and stored frozen (-80℃) until assayed. Determina-
tions were made according to the manufacturer’s specifica-
tions. Specific IgE was measured to house dust mite (Der-
matophagoides pteronyssinius, Dermatophagoides farinae) and cock-
roach (Blatella germanica). Neither skin-prick tests nor IgE
tests were performed on 30 individuals (15 in 1st half of 2000,
9 in 2nd half of 2000, and 5 in 2nd half of 2003).
Statistics
Geometric mean titers and their corresponding 95% con-
fidence intervals (CIs) were obtained by transformation of the
antibody titer levels to a logarithmic scale, subsequent calcula-
tion of arithmetic means and 95% CIs, and back-transforma-
tion of the results to the original scale. Two-way ANOVA
was used to evaluate the difference of antibody titers between
eight periods with age as another grouping factor, and was
followed by Tukey’s multiple comparison test. To compare
antibody titers between the three age groups at each period,
one-way ANOVA was used. Antibody titers were compared
in males and females, and between atopic and non-atopic sub-
A
n
t
i
b
o
d
y
 
t
i
t
e
r
1:640
1:320
1:160
1:80
1:40
1st half of 2000
2nd half of 2000
1st half of 2001
2nd half of 2001
1st half of 2002
2nd half of 2002
1st half of 2003
2nd half of 2003
Fig. 1. Antibody titers to Mycoplasma pneumoniae during the eight
consecutive 6-month periods (2000-2003). Closed circles and
short horizontal bars indicate geometric means and 95% confi-
dence intervals, respectively. *p<0.001; 
� p<0.01, compared with
the titer in the first half of 2000.
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Fig. 2. Distributions of antibody titers to Mycoplasma pneumoni-
ae during the eight consecutive 6-month periods.
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ject groups for each period using the Student’s t test. A p-value
of less than 0.05 was considered statistically significant.
RESULTS
Fig. 1 shows changes in geometric mean antibody titers
over the eight 6-month periods. Two peaks of mean antibody
titers were noted to be separated by 3 yr. Titers peaked in the
second half of 2000 (geometric mean: 262.0, 95% CI: 174.8-
392.8), and then decreased gradually, but remained elevated
for one year (101.7, 78.9-131.2 in the first half of 2001; 61.1,
50.9-73.3 in the second half of 2001), compared to baseline
titer in the first half of 2000 (35.5, 30.8-41.0), and then
achieved baseline (35.6, 31.6-40.1 in the first half of 2002;
38.1, 34.0-42.7 in the second half of 2002; 41.7, 36.3-47.9
in the first half of 2003). However, the peak recurred in the
second half of 2003 (151.8, 118.5-194.4).
Likewise, the frequency of high antibody titers (≥1:640)
peaked in the second half of 2000, gradually declined, and
then re-peaked in the second half of 2003. The frequencies
of high antibody titers in these periods were as follows: 0.8%
and 37.8% in the first and second halves of 2000, 17.7% and
6.6% in the first and second halves of 2001, 0.6% and 1.4%
in the first and second halves of 2002, 3.4% and 30.4% in
the first and second halves of 2003, respectively (Fig. 2). In
addition, the frequency of positive antibody titers (≥1:40)
changed in same manner during the study periods. The 95
and 97.5 percentiles for anti-M. pneumoniae antibody titer
during these periods were 1:160 and 1:320 in the first half
of 2000, 1:20,480 and 1:20,480 in the second half of 2000,
1:1,280 and 1:2,560 in the first half of 2001, 1:640 and
1:1,280 in the second half of 2001, 1:160 and 1:320 in the
first half of 2002, 1:320 and 1:320 in the second half of 2002,
Period
Age in years
No. 0-3 No. 4-6 No. ≥7
1st half of 2000 13 24.8 (19.0-32.2) 29 39.1 (26.5-57.6) 81 36.4 (30.8-43.0)
2nd half of 2000 33 112.0 (55.1-227.5) 44 368.7 (191.6-709.7)* 34 384.4 (183.5-805.4)*
1st half of 2001 52 59.7 (41.2-86.3) 66 135.3 (87.6-208.8)* 29 138.6 (88.1-218.1)*
2nd half of 2001 55 38.0 (28.2-51.3) 60 70.5 (52.4-94.7)* 52 85.5 (61.4-119.1)
�
1st half of 2002 63 27.5 (23.7-32.0) 63 38.3 (30.5-48.0)* 46 45.8 (36.2-58.0)
�
2nd half of 2002 58 26.3 (23.0-30.2) 100 44.4 (37.25-52.9)
� 54 42.7 (33.0-55.1)
�
1st half of 2003 75 34.2 (27.6-42.3) 69 46.5 (35.0-62.0) 59 47.2 (36.3-47.9)
2nd half of 2003 65 86.2 (57.4-129.4) 79 211.9 (138.1-325.1)
� 40 197.0 (142.2-272.9)*
Table 1. Antibody titers to Mycoplasma pneumoniae during the eight consecutive 6-month periods, by age in years
Data are presented as geometric means (95% confidence intervals).
*p<0.05; 
�
p<0.01; 
�
p<0.001, compared with children aged 0 to 3 yr.
Period
Male
No. No.
p
Female
1st half of 2000 91 35.4  32 35.9  NS
(29.9-42.0) (27.2-47.4)
2nd half of 2000 83 249.1 28 304.5 NS
(156.3-396.9) (127.8-725.7)
1st half of 2001 94 99.8 53 105.3 NS
(73.5-135.6) (66.2-167.4)
2nd half of 2001 113 57.8 54 68.6 NS
(46.6-71.8) (48.7-96.6)
1st half of 2002 110 35.7 62 35.4 NS
(30.5-41.8) (29.5-42.4)
2nd half of 2002 138 37.3 74 39.6 NS
(32.15-43.2) (33.1-47.4)
1st half of 2003 131 40.6 72 43.6 NS
(34.0-48.5) (34.8-54.7)
2nd half of 2003 119 147.5 65 160.0 NS
(107.0-203.2) (107.9-237.2)
Table 2. Antibody titers to Mycoplasma pneumoniae during the
eight consecutive 6-month periods, by sex
Data are presented as geometric means (95% confidence intervals).
NS indicates not significant.
Period
Atopy
No. No.
p
Non-atopy
1st half of 2000 78 40.0 30 30.3 NS
(32.9-48.7) (23.8-38.6)
2nd half of 2000 63 210.7 39 277.6 NS
(129.0-344.0) (129.2-596.5)
1st half of 2001 63 106.5 84 98.3 NS
(73.0-155.3) (69.3-139.5)
2nd half of 2001 82 69.3 85 54.1 NS
(53.7-89.3) (41.6-70.3)
1st half of 2002 55 33.5 117 36.6 NS
(27.6-40.7) (31.5-42.6)
2nd half of 2002 89 39.4 123 37.2 NS
(33.3-46.6) (31.8-43.4)
1st half of 2003 67 47.2 136 39.2 NS
(58.6-36.3) (32.8-46.9)
2nd half of 2003 81 177.3 98 143.9 NS
(126.4-248.7) (99.6-207.8)
Table 3. Antibody titers to Mycoplasma pneumoniae during the
eight consecutive 6-month periods, by atopy
Data are presented as geometric means (95% confidence intervals).
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1:320 and 1:640 in the first half of 2003, and 1:5,120 and
1:5,120 in the second half of 2003, respectively.
An examination of antibody titers by age group showed
that the youngest children aged 0-3 yr had lower titers than
those aged 4-6 yr or ≥7 yr during the two peak periods and
during the 2-yr period after the first peak, whereas no signifi-
cant difference was found between the latter two age groups
(Table 1). Table 2 shows antibody titers to M. pneumoniae in
8 study periods by sex. The differences were not statistically
significant, although females had slightly higher titers than
males during all periods except for the first half of 2002. Anti-
body titers to M. pneumoniae were not significantly different
between atopic and non-atopic subjects throughout the study
(Table 3).
DISCUSSION
Antibody titers to M. pneumoniae rose to a peak level in
the second half of 2000 and then decreased gradually, and
re-peaked in the second half of 2003. This was duplicated
by frequencies of high antibody titers (≥1:640). Antibody
titers in children aged 0-3 yr were lower than those in older
children during the two peak periods and during the 2-yr
period following the first peak. Sex and atopy were found to
have no effect on antibody titers throughout the study.
This study was based on a retrospective analysis of results
from testing single sera, obtained in subjects who visited our
outpatient clinic for the first time with acute or chronic res-
piratory symptoms. Serologic tests with paired sera are not
practical in patients with no evidence of lower respiratory
infection with M. pneumoniae. Furthermore, it is difficult to
verify a significant rise of antibody titer in all cases with cur-
rent M. pneumoniae infection because its rise is highly depen-
dent on the time of presentation. Moreover, long persistence
of antibodies following a M. pneumoniae infection (22) may
affect interpretation of our results. Therefore, our data con-
cerning antibody titer to M. pneumoniae may be the conse-
quence of past infection as well as current or recent infection
with M. pneumoniae. It should be noted that the patients re-
viewed in the present study do not precisely match the gen-
eral population with regard to age or sex distribution. Younger
children visit our clinic more frequently, and males outnum-
ber females by about two to one, among those who present
with respiratory symptoms.
A single titer of ≥1:640 is regarded as indicative of recent
M. pneumoniae infection (10, 18). We found that the frequency
of high titers (≥1:640) showed two peaks with a 3-yr inter-
val and these coincided with the peaks of mean antibody titers,
which reflects a cycle of M. pneumoniae epidemics during the
study period. Our results were parallel with studies from dif-
ferent regions of the world, which described the cyclic nature
of epidemics of M. pneumoniae infections (2-6). What governs
the periodicity of these epidemics is not well known. The
community-based transmission of M. pneumoniae diseases
among children may have resulted in protective immunity
in a significant proportion of the population. The duration
of protective immunity in an individual has been estimated
from a few published cases to last about 4 yr with a range of
2 to 10 yr (23-25). Due to the limited duration of protective
immunity, the balance between protected and susceptible
individuals would be lost with time, and thus the following
epidemic could develop.
In the present study, the frequency of higher titers of ≥
1:640 was 37.8% at the first peak (2nd half of 2000). This
frequency is slightly higher than the previously reported preva-
lence of infection of all clinical syndromes caused by M. pneu-
moniae, which ranged from 10 to 35% during epidemic peri-
ods (3, 26-28). A single high titer is unlikely to indicate only
current infection with M. pneumoniae. Furthermore, our sub-
jects may include children with inapparent infection, whereas
the study populations in most previous studies were confined
to those with acute respiratory symptoms. Epidemic patterns
of M. pneumoniae are not identical between different regions
and over time, which may also explain the difference between
our frequency and the prevalence previously reported (3, 14,
27).
The levels of antibody to M. pneumoniae and the proportion
of high titers (≥1:640, data not shown) were not different
between males and females during the study period. Lind
and Bentzon reported significantly more boys than girls in a
seropositive population (27), but provided no explanation for
this difference in gender distribution. However, more recently
Rastawicki et al. demonstrated no gender difference in patients
with M. pneumoniae infection (14), which is in agreement with
the findings of the present study.
We found that antibody titers of children aged 0-3 yr were
lower compared to those of children aged 4-6 yr and ≥7 yr
at the two epidemic peaks and for 2 yr after the first peak, with
no significant difference between the two latter age groups.
Moreover, the frequency of high titers by age group showed
a similar trend (data not shown). This finding is in accordance
with the results of previous seroepidemiologic studies, which
found a low prevalence of M. pneumoniae infection in children
under 3 yr of age (16, 27). But more recently Layani-Milon
et al. demonstrated no significant difference in its infection
rates between children under 4 yr of age and children in other
age groups and adults (28). Other explanations can also be
considered. First, the degree of antibody response to M. pneu-
moniae may be affected by age. A few studies have demon-
strated that most symptomatic disease occurs in older chil-
dren and young adults even though M. pneumoniae infection
is common in infants and young children, and that antibody
response in younger children is of lesser magnitude than in
older children and adults (15, 27, 29). In this context, it has
been presumed that an infection with M. pneumoniae in infancy
may enhance the immune response so that subsequent infec-
tion becomes more severe, resulting in pneumonia with an546 J. Yu, Y. Yoo, D.K. Kim, et al.
increased antibody response as a result of anamnestic recall
(29, 30). Another alternative or concomitant possibility is
that lower antibody levels in children aged 0-3 yr may be due
to different decay rates of antibody by age. Foy et al. demon-
strated that antibody titers to M. pneumoniae declined more
slowly in adults with M. pneumoniae pneumonia than in young
children (<5 yr of age) (22).
Intracellular localization is now appreciated for M. pneumo-
niae (31), against which the host response has been reported
to be associated with cell mediated immunity (29, 32), thus
it is assumed that the activation of cell-mediated immune
responses would be important for protective immunity, like
the association between resistance to Chlamydia pneumoniae,
a well-known intracellular microbe and the induction of Th1
responses (33-36). More recently Ferrari and coworkers found
elevated antibody titers to C. pneumoniae more frequently in
atopic subjects and postulated that atopic disease might be
associated with a less efficient clearance of C. pneumoniae or
with a more severe infection and consequently higher specific
antibody titers (37). While no studies on the relationship
between atopy and M. neumoniae serum antibody titers have
been performed, we speculate that atopic subjects have higher
anti- M. pneumoniae antibody titers than non-atopic subjects
as in the case of C. pneumoniae. However, the present study
indicates that atopy had no effect on antibody titers through-
out the study period, which is contrary to expectation.
In conclusion, over the years 2000-2003, geometric mean
antibody titers and the frequencies of high antibody titers
to M. pneumoniae varied. These changes suggested a cyclic
pattern of M. pneumoniae infection, with two epidemic peaks
separated by 3 yr. However, it must be underlined that the
existence of epidemics was inferred from changes in antibody
titers with time based on testing single sera in the present
study. In addition, age, but neither sex nor atopy, was found
to affect antibody titers.
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